Dealing with FCPA and Other
Investigations Under the New Normal


Tuesday, June 16, 2020 • 1:30 p.m. - 3:00 p.m. EDT

Is your business continuing to function during the COVID-19 pandemic? Has your organization halted operations but plans to reopen soon? Are you wondering how to safely mitigate your risks during this trying period while avoiding investigations from regulatory bodies?

The economic disruptions of the COVID-19 crisis have brought unprecedented stressors to drug and device manufacturers, and your team will need to navigate these complications without relying on actions that may be deemed uncompliant. These obstacles inevitably create incentives and opportunities for fraud — but requirements under the Foreign Corrupt Practices Act of 1977 (FCPA) and other relevant regulations are as critical as ever. Regulators will be expecting companies to foresee potential risk factors and manage them accordingly.

Avoid falling into risky patterns or processes while operating under this new normal. Instead, learn how to adjust your business practices and guard your supply chain against compliancy issues through this detailed FDAnews webinar.

Gail Rodgers and Nancy Sims, attorneys with DLA Piper, will share practical guidelines and tips on maintaining compliance during these shifting and complex times, while also discussing how to manage any potential investigations from regulatory bodies.

Key Webinar Takeaways:

  • Identifying Concerns and Risk
    1. Remote workforce
    2. Reopening business
  • Finding Risk Mitigation Strategies
    1. Compensating for disrupted controls
  • Developing Investigation Protocols
    1. Remote working procedures
    2. Alternative working arrangement processes
  • Implementing Audit Methods
    1. “Pressure testing” for compliance
    2. Remote financial controls
  • Prioritizing Investigation and Compliance Tasks
    1. Applying a risk-based approach

    The COVID-19 crisis has brought extraordinary strains to business practices and compliant supply chains. Ensure your organization is protected before and during an investigation. Join us by registering today.

    Webinar plus USB Audio Recording/Transcript
    Learn more

    $487

    add to cart

    Webinar only
    Learn more

    $287

    add to cart

    24/7 Encore plus USB Audio Recording/Transcript
    Learn more

    $487

    add to cart

    24/7 Encore Presentation
    Learn more

    $287

    add to cart

    USB Audio Recording/Transcript
    Learn more

    $287

    add to cart

     

    Who Will Benefit

    • Pharmaceutical, medical device, or biopharma staff with global practices
    • Lawyers
    • Compliance personnel
    • Investigators
    • Audit committees focused on compliance and investigations

     

    Meet Your Presenters

    Gail Rodgers

    Partner
    DLA Piper

    Gail Rodgers, a partner at DLA Piper, has spent the majority of her career representing multinational pharmaceutical and medical device companies. Rodgers focuses her practice on end-to-end compliance and investigations, including those around bribery and corruption. She has represented multiple Fortune 500 companies in cross-border and multijurisdictional investigations involving allegations of violations of the Foreign Corrupt Practices Act and the UK Bribery Act. She has extensive experience leading teams for corporate internal and government investigations across the globe. Rodgers also conducts proactive global compliance reviews and partners with businesses in implementing controls and remediations and evaluating the efficacy of compliance and investigation programs and protocols. She has a deep scientific background and has represented multiple pharmaceutical and medical device clients in products liability multi-district litigation. She is also the Chair of the DRI Drug and Medical Device Committee. 

    Nancy Sims

    Of Counsel
    DLA Piper

    Nancy Sims, of counsel at DLA Piper, is a commercial litigator who focuses on complex business disputes and investigations. Sims has extensive experience conducting corporate internal investigations and government investigations, including those implicating the Foreign Corrupt Practices Act, UK Bribery Act, and False Claims Act. In addition, her litigation practice involves defending class actions in the consumer, franchise, labor and employment, and insurance spaces. Sims has successfully represented clients in commercial matters based on contract claims, unfair competition, false advertising, fraud, and related business torts. She also serves as the Chair of the Diversity and Inclusion Committee of DLA Piper's Los Angeles Offices and is a member of DLA Piper's North American Pro Bono Committee.

    MII logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 | Fax 703.538.7676 | Toll free 888.838.5578 | Email customerservice@fdanews.com

    © 2020 FDAnews